Are you Dr. Stevens?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 38 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
125 Paterson St
Clinical Academic Building Suite 5200a
New Brunswick, NJ 08901Phone+1 732-235-7217Fax+1 732-212-0713- Is this information wrong?
Summary
- Dr. Randall Stevens, MD is a rheumatologist in New Brunswick, New Jersey. He is currently licensed to practice medicine in New Jersey.
Education & Training
Roger Williams Medical CenterFellowship, Rheumatology, 1985 - 1987
Brown UniversityResidency, Internal Medicine, 1982 - 1985
Case Western Reserve University School of MedicineClass of 1982
Certifications & Licensure
NJ State Medical License 1987 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Rheumatology
Awards, Honors, & Recognition
- Fellow (FACR) American College of Rheumatology
Clinical Trials
- Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis Start of enrollment: 2010 Dec 09
Publications & Presentations
PubMed
- 1863 citationsEfficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.Jonathan C. W. Edwards, Leszek Szczepanski, Jacek Szechiński, Anna Filipowicz-Sosnowska, Paul Emery, D. Close, Randall M Stevens, T. Shaw> ;The New England Journal of Medicine. 2004 Jun 17
- 10 citationsIntravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein, Ro 45-2081 (Lenercept): Results of a dose-finding study in rheumatoid arthritisDaniel E. Furst, Michael H. Weisman, Harold E. Paulus, Kenneth Bulpitt, Michael E. Weinblatt, Richard P. Polisson, Michel Zaug, Johannes Kneer, Philippe van der Auwera...> ;The Journal of Rheumatology. 2003 Oct 1
- 15 citationsIntravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study i...Rolf Rau, Oliver Sander, Piet L. C. M. van Riel, Leo B A van de Putte, Fritz Hasler, Michel Zaug, Johannes Kneer, Philippe van der Auwera, Randall Stevens> ;The Journal of Rheumatology. 2003 Apr 1
Press Mentions
CNTX-4975 Injection Improves OA-Associated Knee PainApril 12th, 2019
Centrexion Therapeutics Announces Fast Track Designation Granted by FDA to CNTX-4975 for Treatment of Morton’s NeuromaFebruary 9th, 2017
Centrexion Therapeutics to Present New Positive Clinical Trial Results on Streamlined CNTX-4975 Administration TechniquesJuly 29th, 2019
Professional Memberships
- Member
- Fellow
Other Languages
- Spanish
